Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis
Main Article Content
Keywords
Abrocitinib, JAK1 inhibitor, Moderate-to-Severe Atopic Dermatitis, Short-Term Efficacy, Disease Severity
References
2. Simpson et al. JAMA Dermatol. 2018;154:903-912.
3. Cibinqo (abrocitinib). Prescribing information. Pfizer Ltd.; September 2021.
4. Cibinqo (abrocitinib). Summary of Product Characteristics. Pfizer Europe; October 2022.
5. Cibinqo (abrocitinib). Prescribing information. Pfizer Labs; January 2022.
6. Simpson EL et al. Lancet. 2020;396:255-266.
7. Silverberg JI et al. JAMA Dermatol. 2020;156:863-873.
8. Bieber T et al. N Engl J Med. 2021;384:1101-1112.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.